Company Quick10K Filing
Guided Therapeutics
10-K 2019-12-31 Filed 2020-04-20
10-Q 2019-09-30 Filed 2020-03-09
10-Q 2019-06-30 Filed 2020-02-11
10-Q 2019-03-31 Filed 2019-07-11
10-K 2018-12-31 Filed 2019-05-08
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-14
S-1 2018-06-14 Public Filing
10-Q 2018-03-31 Filed 2018-05-21
10-K 2017-12-31 Filed 2018-04-17
10-Q 2017-09-30 Filed 2017-11-20
10-Q 2017-06-30 Filed 2017-08-18
10-Q 2017-03-31 Filed 2017-05-22
10-K 2016-12-31 Filed 2017-03-22
10-Q 2016-09-30 Filed 2016-12-05
10-Q 2016-06-30 Filed 2016-08-17
10-Q 2016-03-31 Filed 2016-05-19
10-K 2015-12-31 Filed 2016-03-15
10-Q 2015-09-30 Filed 2015-11-12
10-Q 2015-06-30 Filed 2015-08-13
10-Q 2015-03-31 Filed 2015-05-13
10-K 2014-12-31 Filed 2015-03-25
10-Q 2014-09-30 Filed 2014-11-12
10-Q 2014-06-30 Filed 2014-08-13
10-Q 2014-03-31 Filed 2014-05-15
10-K 2013-12-31 Filed 2014-03-26
10-Q 2013-09-30 Filed 2013-11-13
10-Q 2013-06-30 Filed 2013-08-14
10-Q 2013-03-31 Filed 2013-05-14
10-K 2012-12-31 Filed 2013-03-27
10-Q 2012-09-30 Filed 2012-11-13
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-05-14
10-Q 2011-09-30 Filed 2011-11-14
10-Q 2011-06-30 Filed 2011-08-15
10-Q 2011-03-31 Filed 2011-05-16
10-K 2010-12-31 Filed 2011-03-30
10-Q 2010-09-30 Filed 2010-11-10
10-Q 2010-06-30 Filed 2010-08-12
10-Q 2010-03-31 Filed 2010-05-13
10-K 2009-12-31 Filed 2010-03-23
8-K 2020-03-31 Other Events
8-K 2020-03-31 Other Events
8-K 2019-04-03 Officers
8-K 2018-11-14 Amend Bylaw, Exhibits
8-K 2018-10-25 Shareholder Vote
8-K 2018-08-31 Enter Agreement, Sale of Shares, Amend Bylaw, Exhibits

Guided Therapeutics Financials

GTHP Metrics, Comps, Filings

Quarterly | Annual

Business

We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the sales and marketing of our LuViva® Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light.

LuViva provides a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva improves patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care. We focus on two primary applications for LuViva: first, as a cancer screening tool in the developing world, where infrastructure to support traditional cancer-screening methods is limited or non-existent, and second, as a triage following traditional screening in the developed world, where a high number of false positive results cause a high rate of unnecessary and ultimately costly follow-up tests.

Screening for cervical cancer represents one of the most significant demands on the practice of diagnostic medicine. As cervical cancer is linked to a sexually transmitted disease—the human papillomavirus (HPV)—every woman essentially becomes “at risk” for cervical cancer simply after becoming sexually active. In the developing world, there are approximately 2.0 billion women aged 15 and older who are potentially eligible for screening with LuViva. Guidelines for screening intervals vary across the world, but U.S. guidelines call for screening every three years. Traditionally, the Pap smear screening test, or Pap test, is the primary cervical cancer screening methodology in the developed world. However, in developing countries, cancer screening using Pap tests is expensive and requires infrastructure and skill not currently existing, and not likely to be developed in the near future, in these countries.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
OWC Pharmaceutical Research (OWCP) 0 0% -0.2 362% 1,773 1,467 100 0 6,420 6,420 -1,465
Headhunter Group (HHR)
United States Short Oil Fund (DNO) 0 -0% 0.0 0 0 -600 0 -1,856 -1,856 -0
Immune Therapeutics (IMUN) 0 0.0 -29,381% 8 13,479 0 0 -2,476 -2,475 -6
Juniper Industrial (JIH)
PositiveID Corp (PSID)
Live Current Media (LIVC) 0 2.8 -26% 418 108 0 0 -110 -109 -306
Sun Pacific Holding (SNPW) 0 30% -17.5 -20% 6,669 10,975 260 77 -1,301 -315 5,510
Digatrade Financial (DIGAF) 0 0% 527 778 0 0 0 0 0
Lingerie Fighting Championships (BOTY) 0 -49% 0.2 -8,950,200% 23 -11 90 -10 -2
New Century Resources (NCRE) 0 0.0 0 205 0 0 -18 -17 -0
Arete Industries (ARET)
Renewable Energy Acquisition (REAC) 0 0.0 2,353,600% 0 0 -24 -22 -0
Sundial Growers (SNDL)
Energy Transfer Operating (ETP) 0 27% 5.8 4% 95,247,000 59,636,000 40,493,000 10,886,000 3,786,000 8,016,000 46,523,000
Blue Line Protection Group (BLPG) 0 40% 0.0 -189% 1,661 5,917 3,017 1,201 -3,138 -2,534 -19
ABCO Energy (ABCE) 0 38% 0.1 -173% 411 1,359 1,627 622 -713 -502 -28
Guided Therapeutics (GTHP) 0 332% 0.1 1,462% 404 16,413 28 93 5,908 6,835 439
Endonovo Therapeutics (ENDV) 0 73% -0.8 -301% 3,414 19,980 204 150 -10,268 -9,617 7,448
Dominovas Energy (DNRG)

Balance Sheet ($'000)2011-06-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-31
Cash2,3432,2001,0042,6091,0451,1091,9804006135048542162181,9741723556224141874176417006
Accounts Receivable14911738651071661771121331222334173383582822191902302892260414035641313
Inventory4615240111,19311,1191,2041,1801,1499859121,1191,2531,2381,171773836756577265295280265114112
PP&E641,0331,0881,2702,2201,2631,1371,0302,3278078047062,4325154442,4352,4402,4402172,4412,4412,4412,4412,4412,4412,4412,4412,4412,4412,426
Assets3,3184,3103,0854,7713,4783,5854,3962,9313,3162,5963,8223,7223,0312,5604,0372,7672,5632,3662,3132,0601,4921,4921,508905489527418491236404
Accounts Payable9371,1028631,0407658789868228911,2681,0631,6641,7331,5631,9631,4661,8241,9772,2082,4502,6002,7482,8882,9653,0192,9762,9612,9713,0133,004
Long-Term Debt17404061,7232,6501359944001,33605,068445
Liabilities2,9082,7332,1772,6472,3452,6502,4093,4233,8666,3167,6677,4967,5786,7746,2508,1257,8169,4499,37010,75810,54411,85513,25019,89118,46514,63614,66116,06016,413
Stockholders' Equity4101,5771,133-107-4,465-5,562-9,266-19,402-15,824
Income Statement ($'000)2011-06-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-31
Revenue9137186931,01216722286346191122131510893348218
Cost of Revenue7059991932251455108981199-5114144-239973101
Gross Profit-1213-26-3-59-164-70-703420-104-1362481949610-18955-64-228174217
R&D619714787830813860596499607635892666373305413387290148872089196698369634347
SG&A7791,0008641,3621,2031,4651,0711,0351,4211,6941,5491,5001,1351,2021,2971,4141,0348466027174284491,206420308461193227
Tax
Net Income-496-1,013-986-1,187-1,815-1,750-1,437-2,213-1,562-2,152-2,971-3,198-1,245-1,706-2,191-1,758130-1,879-211-2,010-107-969-2,365-7,1511,0826,866-743-215
Cash Flow ($'000)2011-06-302011-12-312012-03-312012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-03-312014-06-302014-09-302014-12-312015-03-312015-06-302015-09-302015-12-312016-03-312016-06-302016-09-302016-12-312017-03-312017-06-302017-09-302017-12-312018-03-312018-06-302018-09-302018-12-312019-03-31
Cash Operating-663-395-242-417-186
Cash Investing-130-56-1010-104-4-115-25-600-2-60
Cash Financing124411,4792,3311151,3064002,4151,5651,6024822,52459632297655048207394-123270590470207446192